|
John F. Warner, Ph.D., Chief Scientific Officer. Dr. Warner is an experienced executive and scientist who brings to the company over 19 years experience in the biotechnology industry, much of that in the development of therapeutic vaccines. Dr. Warner has also been involved the development of therapeutic gene- and synthetic peptide-based vaccines to induce protective cellular and humoral immune responses for cancer and infectious diseases as well as managing immunology and gene therapy research programs.
Dr. Warner most recently completed a three-year association with Collateral Therapeutics, Inc. as Vice President of Research and Technology advancing their cardiovascular gene therapy and cardiomics programs. Prior to Collateral Therapeutics, Dr. Warner held VP-level positions at Valentis, Inc. and Inex Pharmaceuticals Corporation. Dr. Warner was previously affiliated with Chiron-Viagene (formerly Viagene, Inc.) for eight years (1988-1995) where he served in various supervisory positions including Director, Immunobiology as well as Head of the HIV immunotherapeutic program. This work resulted in the initiation of one of the first gene therapy genetic immunization phase II clinical trials for HIV patients. Dr. Warner was also a Senior Scientist at the Johnson & Johnson Biotechnology Center from 1985 to 1988, developing synthetic peptide vaccines. Dr. Warner's scientific training includes five years as a postdoctoral fellow at The Salk Institute for Biological Studies and the University of California, San Diego involved in the study of innate immune effector systems (cytokines and natural killer cells) and adaptive immune responses (cellular and humoral). Dr. Warner earned his Ph.D. in microbiology/immunology from the State University of New York, Buffalo. | 